MHRA approves remibrutinib for adults with chronic spontaneous urticaria
The MHRA approved remibrutinib (Rhapsido) 25 mg tablets for adults with chronic spontaneous urticaria whose symptoms are inadequately controlled by antihis…
Impact analysis · 40/100 · AI-assisted priority
This score prioritizes research; it does not predict an outcome. Method and limitations.
What happened
The MHRA approved remibrutinib (Rhapsido) 25 mg tablets for adults with chronic spontaneous urticaria whose symptoms are inadequately controlled by antihistamines. The approval was granted through the International Recognition Procedure Route B on 5 August 2026.
Quantitative evidence
- 25 mg tablet dosage
- 925 adult participants in pivotal studies
- exact magnitude of symptom reduction
- statistical significance values
Affected entities
Analysis
The following contextual analysis is AI-assisted and separated from the reported primary-source record above.
Scientific context
Remibrutinib is an oral Bruton's tyrosine kinase inhibitor providing a new mechanism of action in chronic spontaneous urticaria treatment.
Market context
Novartis gains a new oral treatment entry for poorly controlled chronic spontaneous urticaria in UK market.
Legal and regulatory context
The approval followed the International Recognition Procedure, a recognition of non-UK approval to speed UK access.
Related PharmaSignal profiles
Sources
For informational use only. Verify decisions against the linked regulator or primary source.
Evidence & limits
Source: Open the source record
- Record identifier
- e5b46ba7a8145e84b95f0016a646d780d53fc90fa8722cdbcafedab107aa085b
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- 2026-08-06T21:30:23Z
What it supports. The linked authority’s action, within the product, indication, jurisdiction, and procedural stage stated in that record.
Limits. A committee opinion, draft, or announcement does not by itself establish final authorization. The summary and contextual analysis are AI-assisted; a source link does not establish human review.
Connection basis. Related profiles are normalized name mentions in article text. A mention does not establish a legal relationship.